Trametinib
Orphan DrugFDA Approved
Description
Trametinib is a kinase inhibitor indicated, in combination with dabrafenib, for the treatment of anaplastic thyroid cancer with BRAF V600E mutation. It inhibits MEK1 and MEK2 kinases, which are involved in cell signaling and growth.
Indications & Therapeutic Use
Anaplastic thyroid cancer with BRAF V600E mutation
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Trametinib
| Generic Name | Trametinib |
| Brands | 1 brand available |
| Active Ingredient | Trametinib dimethyl sulfoxide |
| Drug Class | Anaplastic thyroid cancer with BRAF V600E mutation |
| Manufacturer | Novartis |
| Dosage Forms | Tablet |
| Medical Code | L01EE07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Reg. Status | FDA Approved |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes